Ironwood Pharmaceuticals, Inc. · NASDAQ:IRWD
Ironwood Pharmaceuticals — Technical Presentation (February 2024)
9 slides from Ironwood Pharmaceuticals's technical presentation, Feb 29, 2024
Slide 1: Phase 3 Clinical Trial of Apraglutide in Patients with SBS-IF
Phase 3 Clinical Trial of Apraglutide in Patients with SBS-IF Topline Results Conference Call February 29, 2024
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including statements about our ability to execute on our vision; our strategy, business, financial position and operations, including
Slide 3: Ironwood Participants
Ironwood Participants Tom McCourt Chief Executive Officer Mike Shetzline, M.D., Ph.D. Chief Medical Officer Sravan Emany Chief Financial Officer Andrew Davis Chief Business Officer 3
Slide 4: Our vision is to be the leading GI healthcare company
Our vision is to be the leading GI healthcare company focused on advancing the treatment of GI diseases and redefining the standard of care for GI patients 4
Slide 5: SBS-IF is a rare, chronic and debilitating condition with impaired intestinal absorptive capacity
SBS-IF is a rare, chronic and debilitating condition with impaired intestinal absorptive capacity1,2 Rare disease with significant complications • SBS-IF is associated with significant medical complications including liver and renal failure, metabolic complications, chronic fatigue, and life- threat
Slide 6: STARS Phase 3 is the largest GLP-2 trial in SBS-IF
STARS Phase 3 Week 24 Week 48 is the largest Apraglutide weekly dosing administration GLP-2 trial PRIMA RY 24- WEEK ENDPOINT ever conducted PS volume reduction in aggregate population in SBS-IF SECONDA RY ENDPOINTS Aggregate and SECONDA RY ENDPOINTS CIC-specific Anatomy-specific 164 SBS-IF patients
Slide 7: Primary Endpoint
Primary Endpoint Apraglutide achieved a statistically significant reduction in weekly PS Volume at week 24 compared to placebo, driven by both stoma and colon-in-continuity populations 7
Slide 8: STARS Phase 3 Trial: Key Secondary Endpoints
STARS Phase 3 Trial: Key Secondary Endpoints Endpoint Data Population Apraglutide: 43.0% Secondary Reduction of at least one day per week of PS Placebo: 27.5% All Patients #1 from baseline at Week 24 Treatment effect: 15.6% (p=0.040) Apraglutide: 25.6% reduction Secondary Relative change from baseli
Slide 9: Key Highlights
• Apraglutide met the primary endpoint of relative change from baseline in actual weekly parenteral support (PS) volume at week 24, driven by both stoma and colon-in-continuity populations • Apraglutide also showed a clinically meaningful improvement at week 24, with patients achieving at least 1 da
Ironwood Pharmaceuticals — Technical Presentation (February 2024) on 6ix